MoonLake Immunotherapeutics inks
three-year technology partnership with Komodo Health to advance
research on inflammatory skin and joint
conditions
MoonLake to tap into Komodo’s technology and
real-world data to unlock the full potential of its next-gen
Nanobody® therapy
San Francisco, US and Zug,
Switzerland, April 10, 2024 – MoonLake Immunotherapeutics
(“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company
focused on creating next-level therapies for inflammatory diseases,
and Komodo Health today announce a new technology partnership to
help improve treatment for people living with inflammatory skin and
joint diseases. The two companies will collaborate to maximize the
impact of MoonLake’s nanobody-based therapy in hidradenitis
suppurativa (HS) and active psoriatic arthritis (PsA), two
underdiagnosed diseases with significant unmet patient needs.
Through this multiyear technology partnership,
MoonLake will utilize Komodo’s Healthcare Map and platform
technologies to enable data-driven decision making across its
clinical operations, medical, marketing, and market access teams.
Komodo’s data and technology applications will support MoonLake’s
in-depth market research, clinical trial site selection,
go-to-market strategies, and patient journey mapping – all aimed at
accelerating the development of new treatment options and improving
outcomes for patients with inflammatory skin and joint
diseases.
Tino Anthamatten, VP Marketing &
Market Access & Pricing, MoonLake Immunotherapeutics,
commented: “We need an experienced technology partner that
can help accelerate our disease insights for our clinical, medical,
and commercial endeavors. Komodo’s data-driven intelligence is
expected to be a critical tool as we work towards commercialization
and delivering transformative therapies to patients.”
Recent research underscores the challenges life
sciences companies face generating data-driven intelligence that
can support decision-making across the product life cycle. On
average, it takes seven months to identify and integrate data
sources before teams can even begin to generate insights.
Using Komodo’s software applications and
Healthcare Map, MoonLake was able to identify important findings,
presented at its R&D day last month, related to the HS market.
The real-world analysis of the U.S. patient population revealed
that between 2016 and 2023, two million unique patients were
diagnosed and treated for HS, not including undiagnosed and
untreated patients. The data also revealed that, on average,
240,000 net new patients get diagnosed and treated each
year. This data helps to substantiate the prevalence of HS as
~2% as stated in the literature. The real-world insights from
Komodo helped validate a future HS market size projected to exceed
$10B by 2035. Today, there is a notably low penetration of current
biologics (around 3%) and a high dropout rate from these current
biologics within the first year (median treatment duration in a
real world setting of 11 months). Furthermore, these insights shed
light on the challenges of care and that individuals living with HS
are being lost in their treatment journey. Over 50-60% of patients
are on long-term antibiotics, and many are concurrently prescribed
steroids and/or opioids. This real-world perspective substantiates
MoonLake’s market size estimates and highlights the need for more
effective therapies.
“We are thrilled to support MoonLake’s efforts
to advance scientific innovation and gain a deeper understanding of
patient journeys and unmet needs for people living with
inflammatory diseases,” said Web Sun, President and Co-Founder,
Komodo Health. “As MoonLake expects to commence phase 3 trials, we
look forward to helping their teams utilize data and analytics to
evaluate the market, develop their go-to-market strategy, and most
importantly help to quickly bring its Nanobody® therapy to market,
once approved, for patients who need it most.”
-Ends-
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage
biopharmaceutical company unlocking the potential of sonelokimab, a
novel investigational Nanobody® for the treatment of inflammatory
disease, to revolutionize outcomes for patients. Sonelokimab
inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F,
and IL-17F/F dimers that drive inflammation. The company’s focus is
on inflammatory diseases with a major unmet need, including
hidradenitis suppurativa and psoriatic arthritis – conditions
affecting millions of people worldwide with a large need for
improved treatment options. MoonLake was founded in 2021 and is
headquartered in Zug, Switzerland. Further information is available
at www.moonlaketx.com. The terms Nanobody® and Nanobodies® are
trademarks of Ablynx, a Sanofi company.
About Komodo HealthKomodo Health is a
technology platform company creating the new standard for
real-world data and analytics by pairing the industry’s most
complete view of patient encounters with enterprise software and
machine learning that connects the dots between individual patient
journeys and large-scale health outcomes. Across Life Sciences,
payers, providers, and developers, Komodo helps its customers
unearth patient-centric insights at scale — marrying clinical data
with advanced algorithms and AI-powered software solutions to
inform decision-making, close gaps in care, address disease burden,
and help enterprises create a more cost-effective, value-driven
healthcare system. For more information, visit
Komodohealth.com.
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic and
progressive inflammatory arthritis associated with psoriasis
primarily affecting the peripheral joints. The clinical features of
PsA are diverse, involving pain, swelling, and stiffness of the
joints, which can result in restricted mobility and
fatigue. PsA occurs in up to 30% of patients with psoriasis,
most commonly those aged between 30 and 60 years. The symptom
burden of PsA can have a substantial negative impact on patient
quality of life. Although the exact mechanism of disease is not
fully understood, evidence suggests that activation of the IL-17
pathway plays an important role in the disease pathophysiology.
About Hidradenitis
SuppurativaHidradenitis suppurativa (HS) is a severely
debilitating chronic skin condition resulting in irreversible
tissue destruction. HS manifests as painful inflammatory skin
lesions, typically around the armpits, groin, and buttocks. Over
time, uncontrolled and inadequately treated inflammation can result
in irreversible tissue destruction and scarring. The disease
affects ~2% of the global population, with three times more females
affected than males. Onset typically occurs in early adulthood and
HS has a profound negative impact on quality of life, with a higher
morbidity than other dermatologic conditions. There is increasing
scientific evidence to support IL-17A- and IL-17F-mediated
inflammation as a key driver of the pathogenesis of HS, with other
identified risk factors including genetics, cigarette smoking, and
obesity.
About Nanobodies®
Nanobodies® represent a new generation of
antibody-derived targeted therapies. They consist of one or more
domains based on the small antigen-binding variable regions of
heavy-chain-only antibodies (VHH). Nanobodies® have a number of
potential advantages over traditional antibodies, including their
small size, enhanced tissue penetration, resistance to temperature
changes, ease of manufacturing, and their ability to be designed
into multivalent therapeutic molecules with bespoke target
combinations.
The terms Nanobody® and Nanobodies® are
trademarks of Ablynx, a Sanofi company.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains certain
“forward-looking statements” within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, statements regarding
MoonLake’s expectations, hopes, beliefs, intentions or strategies
regarding the future including, without limitation, statements
regarding: plans for clinical trials and research and development
programs; including the initiation of clinical programs in new
indications; anticipated support from regulatory agencies with
respect to the MoonLake’s development plans, anticipated size and
timing of enrollment for the VELA trial, the sufficiency of data
from the VELA trial to support regulatory filings in the US and EU,
the anticipated trial design for the VELA trial and the timing of
expected readouts; MoonLake’s expectations regarding the potential
market size for HS; the MoonLake’s plans with respect to the
commencement of a Phase 3 trial in PsA; and the efficacy of
MoonLake’s products, if approved, including in relation to other
products. In addition, any statements that refer to projections,
forecasts, or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking statements. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “would” and similar expressions may identify
forward-looking statements, but the absence of these words does not
mean that statement is not forward looking.
Forward-looking statements are based on current
expectations and assumptions that, while considered reasonable by
MoonLake and its management, as the case may be, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with MoonLake’s business in
general and limited operating history, difficulty enrolling
patients in clinical trials, and reliance on third parties to
conduct and support its clinical trials, and the other risks
described in or incorporated by reference into MoonLake’s Annual
Report on Form 10-K for the year ended December 31, 2023 and
subsequent filings with the Securities and Exchange Commission.
Nothing in this press release should be regarded
as a representation by any person that the forward-looking
statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be
achieved. You should not place undue reliance on forward-looking
statements in this press release, which speak only as of the date
they are made and are qualified in their entirety by reference to
the cautionary statements herein. MoonLake does not undertake or
accept any duty to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or in the events, conditions or circumstances on which
any such statement is based.
Media Contacts:media@komodohealth.com
MoonLake Immunotherapeutics MediaPatricia Marques de
Sousamedia@moonlaketx.com
ICR ConsiliumMary-Jane Elliott, Namrata Taak, Ashley TappTel.:
+44 (0) 20 3709 5700moonlake@consilium-cooms.com
- Komodo x MoonLake PR_4.10.24 FINAL
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Nov 2024 to Dec 2024
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Dec 2023 to Dec 2024
